Women with advanced form womb cancer have been given fresh hope after a new treatment was given the green light for ...

MSD – known as Merck & Co in the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been ...

New first-line option for patients with pMMR and dMMR tumours in England NICE has recommended KEYTRUDA (pembrolizumab) with ...

The UK’s National Institute for Health and Care Excellence (NICE) on August 6 recommended the use of US pharma giant Merck & ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

Merck is an industry giant that has proved time and again it can innovate for the future. Ventas has positioned itself to ...

More cancer patients in the Taupō region can now receive treatment closer to home, following an expansion of chemotherapy services at Taupō Hospital, Healt ...

MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

The highest-paying dividend stocks in the Dow Jones Industrial Average right now are Verizon Communications (NYSE: VZ), ...

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting ...

President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...